Latest Carboplatin Stories
Adding topotecan to carboplatin plus paclitaxel, the standard treatment for ovarian cancer, does not improve progression-free survival in patients and leads to greater toxicity.
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.
COLUMBIA, Md., Sept.
CALGARY, July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
CALGARY, July 19 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer (NSCLC).
The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer.
Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival.
CALGARY, June 7 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a poster presentation covering updated results of its Phase I/II U.K.
The combination of two different chemotherapies and a previously approved treatment for kidney and liver cancers is not effective against advanced melanoma.
- Growing in low tufty patches.